FY2026 EPS Estimates for Halozyme Therapeutics, Inc. (NASDAQ:HALO) Raised by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities researchers at Zacks Research raised their FY2026 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued to investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will earn $5.16 per share for the year, up from their previous forecast of $5.08. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.45 per share.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). The business had revenue of $230.04 million during the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%.

Other equities analysts have also issued research reports about the company. TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. Benchmark restated a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. The Goldman Sachs Group decreased their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, January 18th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, April 17th. Finally, TD Cowen began coverage on shares of Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price objective for the company. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $53.29.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $39.12 on Wednesday. The firm has a market capitalization of $4.97 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 0.45 and a beta of 1.25. The business’s fifty day moving average price is $39.71 and its 200 day moving average price is $37.79. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50. Halozyme Therapeutics has a 12 month low of $29.85 and a 12 month high of $45.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in HALO. Rise Advisors LLC purchased a new position in Halozyme Therapeutics during the first quarter worth about $25,000. Principal Securities Inc. acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at approximately $34,000. First Horizon Advisors Inc. lifted its position in shares of Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 293 shares during the period. Parkside Financial Bank & Trust acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at approximately $64,000. Finally, Headlands Technologies LLC lifted its position in shares of Halozyme Therapeutics by 1,068.2% during the 4th quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 1,613 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $39.55, for a total transaction of $395,500.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at $6,191,868.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders sold 30,000 shares of company stock worth $1,196,800. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.